-
Electronic (PDF - 1 Year Sub.)
-
Electronic (Online Access)
-
Enterprisewide
-
Enterprisewide
The Pharmaceutical Market: France
Espicom Business Intelligence Ltd, May 2012, Pages: 82
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Executive Summary
THE PHARMACEUTICAL MARKET: FRANCE - REVIEW
France ranks alongside the UK as the second largest country in Europe in terms of population and GDP. Per capita spending on medicines continues to be one of the highest within Europe, despite measures to reduce drug consumption. The historically high levels of drug consumption stem from the fact that French patients pay relatively little for their medicines. The majority of costs are met by statutory health insurance, backed up by supplementary health insurance, which is held by over 90% of the population. Moreover, patients suffering from chronic conditions, who account for over 60% of health spending, have been exempt from drug co-payments, although new restrictions were recently introduced limiting 100% reimbursement to those drugs that are necessary to treat the chronic condition.
In June 2011, the Minister of Health Xavier Bertrand announced a radical reform of the French regulatory procedure. The move followed the controversy surrounding Servier’s drug Mediator, a diabetes treatment that was also used by many patients as a weight loss aid. There have been allegations that fatal side effects of the drug were hushed up by the company and also ignored by the AFSSAPS. The drug was withdrawn from the market in November 2009 due to safety concerns, and analysis has now revealed it could be responsible for up to 2,000 deaths. As part of the reform, the AFSSAPS will be changed to the National Agency for the Safety of Medicines (ANSM), and the way it is financed will be changed as it currently obtains around 80% of its funding from pharmaceutical companies. Another part of the reform is to publish a list of links between experts and laboratories, and the amount of money paid for services completed. This part of the reform has started on the 19,000 drugs in France, of which 12,000 are on the market, and Takeda’s drug Actos was the first to be removed from the market due to the new regulations. The new law also restricts visits by sales representatives and bans the pharmaceutical industry from funding medical education.
France has one of the highest pharmaceutical per capita consumption levels in the world. The French pharmaceutical market is also one of the world’s largest. The CAGR has been comparatively low and growth is expected to be comparatively low between 2012 and 2017, with government cost-containment programmes exerting downward pressure on reimbursable products. The hospital market has been much more dynamic with growth rates twice this figure in recent years, although growth rates are now falling due to greater regulatory controls in this sector and fewer innovative drugs coming to market. The underdeveloped generics market is undergoing rapid expansion, boosted by government incentives and the loss of patent protection for several high-volume products. The stagnating OTC market has also started to expand, as a result of government moves to end reimbursement for a wide range of products assigned a low medical value rating.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Related Pages:
Pharmaceutical Market Finland
Pharmaceutical Market Germany
More Information...
HIGHLY DETAILED REPORT CONTENT
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
GLOBAL COMPANY INTELLIGENCE
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
